ProPhase Labs, Inc.

PRPH Healthcare Diagnostics & Research

In the quarter to June 2026, revenue fell 18.9%, EPS grew 80.0%, free cash flow grew 56.7% and total debt rose 19.4%, each against the same quarter a year earlier.

0.01 0.00 0.00%
Market cap
$1.2M
P/E
0.0×
Fwd P/E
−0.6×
Dividend yield
—
F-score
4/9
Altman Z
−3.59
Beneish M
−4.90
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
3.78 0.88 0.33 0.40
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(5.48) (3.11) (1.48) (16.17)
P/B ratio
2.79 1.09 0.00 0.00
Price to Tangible BV
0.00 0.00 0.00 0.00
EV/Sales
4.08 2.19 2.04 2.19
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
(1.94) (1.14) (1.21) (1.25)
EV/FCF
(1.95) (1.16) (1.23) (1.25)
Quick Ratio
0.07 0.03 0.03 0.03
Current Ratio
0.14 0.06 0.06 0.05
Net Debt/EBITDA
(0.55) (4.26) (4.99) (6.13)
Debt/Assets
2.92% 9.68% 9.97% 9.88%
Debt/Equity
0.28 1.65 (9.54) (1.82)
Asset Turnover
0.06 0.07 0.06 0.06
Operating CF/Net income
0.51 0.17 0.14 0.03
Capex/Depreciation
0.00 0.00 0.01 0.00
Interest Coverage
(3.08) (1.34) (4.00) (3.34)
Research and Development Expense of Revenue
0.68% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
524.92% 761.86% 579.92% 283.98%
Intangible Assets out of Total Assets
0.18 0.19 0.18 0.17
Share Based Compensation of Revenue
48.81% 55.23% 81.59% 37.09%
Graham Net Nets
(2.67) (13.93) (50.73) (45.76)
Graham Number
0.00 0.00 1.92 3.45
Earnings Yield
(389.80%) (386.58%) (3,632.89%) (2,655.11%)
Free Cash Flow Yield
(55.22%) (215.29%) (508.06%) (438.39%)
Revenue per Share
0.21 0.09 0.04 0.07
Operating CF per Share
(0.84) (0.14) (0.06) (0.01)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.84) (0.14) (0.06) (0.01)
Cash per Share
0.10 0.01 0.00 0.00
Shareholders Equity per Share
1.65 0.41 (0.05) (0.22)
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
1.65 0.41 (0.05) (0.22)
Free Cash Flow
(3.49) (1.23) (0.74) (0.08)
Working Capital
(47.51) (49.93) (52.99) (55.28)
Capital Expenditures
0.00 0.00 0.01 0.00
Net Current Asset Value
(51.07) (53.21) (56.23) (57.72)
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 (0.03) 0.00
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
17.46 10.80 10.87 10.81
Average Payables
28.65 27.14 27.53 29.20
Average Inventory
2.12 0.61 0.61 0.45
Average Assets
78.76 61.54 54.42 49.73
Average Common Equity
22.49 5.43 7.25 4.16

Fold the line items

Columns are period end dates